MK-4166
Biological
Merck Sharp & Dohme Corporation
Total Payments
$1.2M
Transactions
180
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $22,267 | 12 | 0 |
| 2019 | $221,299 | 31 | 0 |
| 2018 | $262,361 | 48 | 0 |
| 2017 | $694,048 | 89 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 180 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination with Pembrolizumabin Subjects with Advanced Malignancies | Merck Sharp & Dohme Corporation | $1.2M | 0 |
| Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination with Pembrolizumab in Subjects with Advanced Malignancies | Merck Sharp & Dohme Corporation | $22,267 | 0 |
Top Doctors Receiving Payments for MK-4166
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $1.2M | 180 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.2M
- Total Doctors 0
- Transactions 180
About MK-4166
MK-4166 is a biological associated with $1.2M in payments to 0 healthcare providers, recorded across 180 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $22,267 was paid across 12 transactions to 0 doctors.
The most common payment nature for MK-4166 is "Unspecified" ($1.2M, 100.0% of total).
MK-4166 is associated with 2 research studies, including "Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination with Pembrolizumabin Subjects with Advanced Malignancies" ($1.2M).